A retrospective survey of patients with malignant gliomas treated in the neuro-oncological care system under the Universal National Health Insurance program in Taiwan

Journal of Clinical Neuroscience

Volumn 18, Issue 6, 2011, Pages 784-788

  Huang, Yin Cheng ^a   Wei, Kuo Chen ^a   Chang, Chin Hong ^b   Yang, Jen Tsung ^a   Ho, Jih Tsun ^c   Shen, Chiung Chyi ^d   Su, Chain Fa ^e   Cho, Der Yang ^f   Ma, Hsin I ^g   Lin, Jia Wei ^h   Lee, E Jian ⁱ   Wu, Jionn Jong ^j   Tsai, Ming Dar ^k   Chang, Cheng Kuei ^l   Howng, Shen Long ^m   Chang, Chen Nen ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c Chang Gung Medical Foundation   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^j FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^k FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^l TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^m KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

Chemotherapy; Malignant glioma; Radiation therapy; Surgery; Universal health insurance

Indexed keywords

CARMUSTINE; DENDRITIC CELL VACCINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER GRADING; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HEALTH CARE SYSTEM; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NATIONAL HEALTH INSURANCE; NEUROPATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; SURVIVAL RATE; TAIWAN; WORLD HEALTH ORGANIZATION;

ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NEOPLASM RECURRENCE, LOCAL; NEUROLOGY; RETROSPECTIVE STUDIES; TAIWAN;

EID: 79955905732     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2010.10.016     Document Type: Article

References (15)

1. Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 2008;148:258-67. (Pubitemid 351688355)
2. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 2003;22:61-76.
3. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003;99:467-73. (Pubitemid 37040405)
4. Lin CL, Lieu AS, Lee KS, et al. The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol 2003;60:402-6; discussion 6.
5. Yang TM, Wang HC, Lin YJ, et al. Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma. Surg Neurol 2008;70(Suppl. 1):60-3.
6. Yeh SA, Leung SW, Sun LM, et al. Postoperative radiotherapy for supratentorial malignant gliomas. J Neurooncol 1999;42:183-7. (Pubitemid 29322155)
7. Lu JF, Hsiao WC. Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff (Millwood) 2003;22:77-88. (Pubitemid 41388746)
8. Chen LC, Schafheutle EI, Noyce PR. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan. Res Social Adm Pharm 2009;5:211-24.
9. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
10. Romanelli P, Conti A, Pontoriero A, et al. Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme. Neurosurg. Focus 2009;27:E8.
11. Shoshan Y, Wygoda M, Umansky F. Stereotactic radiosurgery and fractionated stereotactic radiotherapy: background, definitions, applications. Isr Med Assoc J 2005;7:597-9. (Pubitemid 41309229)
12. Sampson JH, Archer GE, Mitchell DA, et al. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008;20:267-75.
13. Gu J-H, Li G. Dendritic cell-based immunotherapy for malignant glioma. Neurosci Bull 2008;24:39-44. (Pubitemid 351903621)
14. Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 2008;10:79-87. (Pubitemid 351250903)
15. Anderson E, Grant R, Lewis SC, et al. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Br J Neurosurg 2008;22:339-49. (Pubitemid 351878617)